


Mass Spectrometry Strategies for Rapid and Artifact-Free Antibody Structure Analysis


Yury O. Tsybin

Ecole Polytechnique Fédérale de Lausanne, Switzerland



20 June 2014, Baltimore, MD



Antibodies Structural Questions



Schematics of immunoglobulin G1, IgG1
CDRs: Complementarity Determining Regions

- Sequence verification, **fast & artifact-free**
- **Modifications:** oxidation, deamidation, glycosylation...
- CDRs **connectivity**
- Light&heavy chains **pairing**
- **Mixtures:** LC-MS/MS
- *de novo* sequencing
- Disulfide bond scrambling
- Ligand, drug binding (ADC)
- Aggregation
- High order structure

MS/MS-Based Approaches For IgG Analysis




Throughput, digestion artifacts

Precursor ion size, charge state

Proteoform ID

MS/MS-Based Approaches For IgG Analysis




Throughput, digestion artifacts

Precursor ion size, charge state

Proteoform ID

Extended bottom-up MS for IgG characterization




Sap9 → aspartic protease from *Candida albicans*, active in a **broad pH range**, with cleavage preference for dibasic sites (e. g., RR, KK) or proximal dibasic sites in slightly acidic conditions.

Sap 9 digestion
pH 5.5



3 – 7 kDa

EXTENDED Bottom-Up




IgG deamidation:

- Major quality attribute
- Alters antigen binding when occurs in CDRs
- Classic bottom-up: Basic digestion pH → artifactual deamidation
- Inefficient enzyme digestion at lower pH

Sap9 digestion:

- Fast: 1 hour
- Slightly acidic pH: 5.5 – 6.0: No artifactual deamidation

Extended bottom-up MS for IgG characterization




Sap 9 digestion
pH 5.5



3 – 7 kDa

EXTENDED Bottom-Up



Sap9 → aspartic protease from *Candida albicans*, active in a **broad pH range**, with cleavage preference for dibasic sites (e. g., RR, KK) or proximal dibasic sites in slightly acidic conditions.

Trastuzumab

Light chain: Sequence coverage: 100 %

```

D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D V I (N/n) T I A V A W Y Q Q R K P G K A P K L L I Y S A S
F L Y S G V I P S R F S G S R S G T D F T L T I S S L Q P E D F A I T Y F C Q H Y T T P P T F G Q G T K V E I K R T
V A A P S M F I F P P S D E Q L K S G T A S V V C L L N N F Y P R E A K V Q W K V D N A L Q S G (N/n) I
S Q E S V T E Q D S K D S T Y S L S S T L T L S K I A D Y E K H K V Y A C E V T H Q G L S S P V T K S F N I
R G E L C
    
```

(Average: 3.5 kDa, 4.0+)

Heavy chain: Sequence coverage: 100 %

```


E I V Q L V E S G G G L V Q P G G S L R L S C A A S G F N I K D T Y I H W V R I Q A P G K G L E W V A R I Y P
T I (N/n) G Y T R Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C S R W G G D G I
F Y A M D Y W G Q G T L V T V S I A S T K G P S M F P L A P S S K I S T S G G T A A L G C L V K D Y F P E P V T V S I
W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S S S L G T Q T Y I C N M N H K P S N T K V D I
K K V E P K S C D K T H T C P P C P A P E L L G G P S V F L F P P K P K D T L M I S R T P E V T C V V V D I
V S H E D P E V K F N W Y M D G V E M H N A K T K P R E E Q Y (N/n) S T Y R V M S V L T V L H Q D W L N G K I
E Y K C K V S (N/n) K I A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P S R I E E M T K N Q V S L T C
L M K G F Y P S D I A V E W E S N G Q P E (N/n) N Y K T T P P V L D S D G S F F L Y S K L T V D R S R W
Q Q G (N/n) V F S C S V M H E A L H N H Y T Q K S I L S L S I P G
    
```

(Average: 3.3 kDa, 4.2+)

○ CDR deamidation hotspot


Deamidation assesment by e-bottom-up with Sap9

Sap 9 Lc peptide containing N₃₀




Trastuzumab


Sap 9 Hc peptide containing N₅₅



Tryptic Lc peptide containing N₃₀




Tryptic Hc peptide containing N₅₅




Deamidation assesment by e-bottom-up with Sap9


Sap 9 Lc peptide containing N₃₀




ETD spectrum with IsoAsp₅₅ diagnostic ions



Tryptic Lc peptide containing N₃₀




Tryptic Hc peptide containing N₅₅



Six IgGs mixture by e-bottom-up with Sap9


Rituximab-Hc

ASIGYITFTTSYINMHHVWIKQTPGRGLEI
 WLIIGAIITYPIGHGIDTTSYINQIKFIKGK




Panitumumab-Hc

QVQLIQEISIGPGILVHKIPISETLISLITCI
 VLSIGSIVSISIGDIYIWTIWIHRQSPGK




Natalizumab-Hc

DIYIITHWVIRQIAPGQRLIEWMGRIDPAINGYITIKYID




Rituximab-Lc

ASSIVSYIHWIFQIQKIPGISTSPIKIPWIYAITSN
 ILAISGIVPVIRIFSIGSGGTTSYISLITISIR




Panitumumab-Lc

DASNLIEITGVPSIRIFISIGSISGTDIFITFTISL
 ISLILQPEIDIIAITYFCQHFIDLPLAFGGGKVEIK




Natalizumab-Lc

DIQLMHTQSPISLISLISVIGRVTITC
 KITISQDINKYMLAWYQQTPGKAPRLILIHYSIA



Identification of proteotypic peptides with two CDRs;
 Sequence coverage > 90 % in a mixture

MS/MS-Based Approaches For IgG Analysis




Throughput, digestion artifacts


Precursor ion size, charge state

Proteoform ID

Top-Down View on IgG: 150, 100, 50, 25 kDa subunits



Middle-up and –down MS workflows: **Ides** proteolysis



Data analysis


- IdeS cleaves in formulation buffer: no artifacts
- Quick protocol, sample preparation in less than 1h
- CDRs 1, 2 & 3 sequenced

- Up to - 68% sequence coverage
- Glycosylation site identified
- Effective in IgG mixtures analysis

Oxidation assesment with middle-down MS


Methionine oxidation:

- In Fc it alters binding to neonatal Fc receptor
- Negative impact on IgG half life and pharmacokinetics




Tryptophane oxidation:

- If in CDR it alters binding to antigen




Oxidation assesment with middle-down (ETD) MS


Middle-Down MS:
confident assignment
of the oxidation sites



Fab (50 kDa) analysis with middle-down (ETD) MS




above hinge
region cleavage
Papain




The disulfide bond
in the Fab is kept


Mixture of
3 IgGs




Fab (50 kDa) analysis with middle-down (ETD) MS



Pairing information @ Fab level with middle-down MS




Assignment of ETD product ions



- S-S bonds may remain intact upon ETD MS/MS
- Current top-down search algorithms do not account for these ions
- **A dedicated ETD product ion analysis tool has been developed to assign these S-S-bond containing ions**

Pairing information @ Fab level with middle-down MS




Pairing information @ Fab level with middle-down MS

Trastuzumab, ETD product ions with the interchain S-S bond cleaved


Light chain: Sequence coverage 23.0 %

D-I-Q[M-T-Q]S-P-S[S-L]S-A[S]V[G]D[R]V[T-I-T]C[R-A-S-Q-D-V-N-T-A-V-A-W-Y-Q-Q-K-P-
G-K-A-P-K-L-L-I-Y-S-A-S-F-L-Y-S-G-V-P-S-R-F-S-G-S-R-S-G-T-D-F-T-L-T-I-S-S-L-Q-P-
E-D-F-A-T-Y-Y-C[Q-Q-H]Y-T-T-P-P[T-F]G[Q]G[T]K[V]E[I]K[R]T-V[A]A-P[S]V[F]I[F-P-P]
S[D]E[Q]L[K-S-G-T-A-S-V-V]C-L-L-N-N-F-Y-P-R-E-A-K-V-Q-W-K-V-D-N-A-L-Q-S-G-N-S-Q-
E-S-V-T-E-Q-D-S-K-D-S-T-Y-S-L-S-S-T-L-T-L-S-K-A-D-Y-E-K-H-K-V-Y-A-C-E-V-T[H]Q[G-
L[S-S-P]V-T[K-S]F-N[R]G-E]C-



Heavy chain Fd: Sequence coverage 26.1 %

E-V-Q-L-V-E-S[G-G-G-L-V]Q-P[G]G[S]L[R-L-S]C-A[A-S]G-F-N[I-K-D-T-Y-I-H-W-V-R-Q-A-
P-G-K-G-L[E-W-V-A-R-I]Y-P-T-N-G-Y-T-R-Y-A-D-S-V-K-G-R-F-T-I-S-A-D-T-S-K-N-T-A-Y-
L-Q[M-N-S-L-R-A-E-D-T-A-V-Y-Y]C-S[R]W[G]G[D]G[F]Y[A]M[D]Y[W]G[Q]G[T]L[V]T[V]S[S]
A[S-T]K[G-P-S-V]F-P-L[A-P-S]S-K-S[T-S-G-G-T-A-A-L-G]C-L-V-K-D-Y-F-P-E-P-V-T-V-S-
W-N-S-G-A-L-T-S-G-V-H-T-F-P-A-V-L-Q-S-S-G-L-Y-S-L-S-S-V-V-T-V-P-S-S-S-L-G-T-Q-T-
Y-I-C-N-V[N]H[K-P]S-N-T[K]V[D]K[K-V]E-P[K]S]C-D-K-T-H-



Pairing information @ Fab level with middle-down MS




Trastuzumab, ETD product ions with the interchain S-S bond **NOT** cleaved

Light chain: Sequence coverage 16.4 %

·D I Q M T Q S P S L S L S A L S V G D R L V T I T L C R A S Q D V N T A V A W Y Q Q K P
 ·G K A P K L L I Y S A S F L Y S G V P S R F S G S R S G T D F T L T I S S L Q P
 ·E D F A T Y Y C L Q Q H L Y L T T P P T F G Q L L L L L E I L K R L T V A A P S L V F L I F P P
 ·S D E Q L K S G T A S V V C L L N N F Y P R E A K V Q W K V D N A L Q S G N S Q
 ·E S V T E Q D S K D S T Y S L S S T L T L S K A D Y E K H K V Y A C L E V L T L H L Q L G
 L L S L S P V T L K L S F L N R G L E L C

Heavy chain Fd: Sequence coverage 16.8 %

·E V Q L V E S G G G L V Q P L G G L S L R L S C A A S G F N I K D T Y I H W V R Q A
 ·P G K G L E W V A R I Y P T N G Y T R Y A D S V K G R F T I S A D T S K N T A Y
 ·L Q M N S L R A E D T A V Y Y C S R L W G G L D G F L Y A L M D L Y W G Q G T L L V T V L S L S
 ·A L S L L L K G P S V F P L A P S L S K L S T L S G G L T A A L G L C L V K D Y F P E P V T V S
 ·W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S S S L G T Q T
 ·Y I C L N V N H L K P S N T L K L V D L K L V E P K L S L C D K T H




Intermediate Conclusions

- **Extended bottom-up MS for IgG analysis:**
 - Faster sample preparation than in bottom-up MS
 - More effective sequencing of single and mixture IgGs
 - **Deamidation** assesment without artifact introduction
 - Identification of heavy and light chains from sera
- **Middle-down (ETD) MS for IgG analysis:**
 - 25 kDa subunits (Ides):
 - Sequencing
 - PTMs characterization: **Oxidation** sites assesment
 - 50 kDa subunits (Fab, Papain):
 - Identification of Lc and Hc chain **pairs**
 - Assignment of disulfide-bridged ETD product ions

Challenge: High complexity serum mixtures of IgGs → Improving separation, fractionation (High IgG structural similarity)

MS/MS-Based Approaches For IgG Analysis




Throughput, digestion artifacts

Precursor ion size, charge state


Proteoform ID

Intact Antibody Mass Analysis: Proteoforms




Adalimumab
15k resolution

MW of proteoforms!




Intact Antibody Structure Analysis: ETD MS/MS





Intact Antibody Structure Analysis: ETD MS/MS


Averaging many MS scans (in time or in **spectral domain**) for improving SNR:



Narrow i.w.: 24.4%
 Wide i.w.: 27.1%
 Total: 32.7%



Summary: MS Approaches For IgG Analysis



TDP: Top-Down Proteomics
MDP: Middle-Down Proteomics
BUP: Bottom-Up Proteomics

	<i>Pros</i>	<i>Cons</i>
TDP: ETD/HCD	<ul style="list-style-type: none"> No artifact induction Proteoform ID 	<ul style="list-style-type: none"> ~30% sequence coverage Only CDR3
MDP: Papain	<ul style="list-style-type: none"> ~2x sequence coverage TDP Large PTM ID Chain pairing 	<ul style="list-style-type: none"> Long protocol Non specific cleavages Difficult small PTM ID (deam.)
MDP: Ides	<ul style="list-style-type: none"> No artifact induction (fast) Specific cleav. 	<ul style="list-style-type: none"> Difficult small PTM ID (deam.) 70% seq. cov.
Extended BUP: Chemicals (CNBr, NTCB)	<ul style="list-style-type: none"> No substrate specificity Large (>3 kDa) peptides 	<ul style="list-style-type: none"> Stoichiometry is very important Special handling conditions needed Secondary reactions
Extended BUP: Sap9	<ul style="list-style-type: none"> Works in acidic pH, fast (1 h) 100% seq. cov. Large peptides Small PTM ID 	<ul style="list-style-type: none"> Not very specific, overlapping peptides Longer digestion times lead to shorter peptides

Acknowledgements



Anna Lobas, Mikhail Gorshkov (Russian Academy of Sciences, Moscow)
Konstantin Ayzikov, Alexander Makarov (Thermo Scientific, Bremen)
Alain Beck (Pierre Fabre Laboratories, France)
Tariq Khan, Sai Reddy (ETHZ, Zurich)

